Key result
Higher baseline serum thrombospondin-2 levels were independently associated with an increased risk of incident heart failure hospitalization in patients with type 2 diabetes.
Why the study?
Prior studies linking circulating thrombospondin-2 (TSP2) levels to heart failure included few patients with type 2 diabetes, a condition known to induce TSP2 expression and increase heart failure risk.
Does elevated baseline serum thrombospondin-2 (TSP2) predict incident heart failure hospitalization and diastolic dysfunction in patients with type 2 diabetes?
Cohort (n=4,949)
No
Does elevated baseline serum thrombospondin-2 (TSP2) predict incident heart failure hospitalization and diastolic dysfunction in patients with type 2 diabetes?
Answers are grounded in this paper and cite their sources.
Elevated circulating TSP2 levels independently predict incident heart failure hospitalization and deterioration of diastolic function in patients with type 2 diabetes.
BACKGROUND: Circulating thrombospondin-2 (TSP2) levels were associated with the development of heart failure (HF) in recent studies. However, these studies included only a minority of patients with type 2 diabetes, which is associated with an increased HF risk. As hyperglycemia induces TSP2 expression and its tissue expression increases in type 2 diabetes, we investigated the prospective association of circulating TSP2 with incident HF hospitalization (HHF), and its associations with longitudinal changes of echocardiographic parameters in type 2 diabetes. METHODS: Baseline serum TSP2 levels were measured in 4949 patients with type 2 diabetes to determine its association with incident HHF using multivariable Cox regression analysis. In the echocardiographic study, baseline serum TSP2 levels were measured in another 146 patients with type 2 diabetes but without cardiovascular diseases who underwent detailed transthoracic echocardiography at baseline and after 1 year. RESULTS: Over a median follow-up of 7.8 years, 330 of 4949 patients (6.7%) developed incident HHF. Baseline serum TSP2 levels were independently associated with the development of HHF (HR 1.31, 95%CI 1.06-1.62, p = 0.014) after adjustments for baseline conventional cardiovascular risk factors, atrial fibrillation, estimated glomerular filtration rate, albuminuria and high-sensitivity C-reactive protein level, use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, loop-diuretics, aspirin, insulin, metformin and sodium-glucose co-transporter 2 inhibitors. Moreover, baseline serum TSP2 levels were independently associated with increase in average E/e' and left atrial volume index (p = 0.04 and < 0.01, respectively). CONCLUSION: Serum TSP2 levels were independently associated with both incident HHF and deterioration in diastolic function in type 2 diabetes. TRIAL REGISTRATION: Not Applicable.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) conducted a cohort in Type 2 diabetes (n=4,949). Baseline serum thrombospondin-2 (TSP2) level vs. Lower baseline serum TSP2 level was evaluated on Incident heart failure hospitalization (HHF) (HR 1.31, 95% CI 1.06-1.62, p=0.014). Higher baseline serum thrombospondin-2 levels were independently associated with an increased risk of incident heart failure hospitalization in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: